Vasopressin in the cardiac surgery intensive care unit

American Journal of Critical Care

Volumn 11, Issue 4, 2002, Pages 326-332

  Albright, Tracy N ^a   Zimmerman, Michael A ^a   Selzman, Craig H ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VASOPRESSIN DERIVATIVE;

CARDIOPULMONARY BYPASS; CONTINUING EDUCATION; CORONARY CARE UNIT; HUMAN; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; REVIEW; SHOCK; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; UNITED STATES;

CARDIOPULMONARY BYPASS; CORONARY CARE UNITS; EDUCATION, CONTINUING; HUMANS; PRACTICE GUIDELINES; SHOCK, SURGICAL; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; UNITED STATES; VASOPRESSINS;

EID: 0036635855     PISSN: 10623264     EISSN: None     Source Type: Journal    
DOI: 10.4037/ajcc2002.11.4.326     Document Type: Article

References (32)

1. Argenziano M, Choudhri AF, Oz MC, Rose EA, Smith CR, Landry DW. A prospective randomized trial of arginine vasopressin in the treatment of vasodilatory shock after left ventricular assist device placement. Circulation. 1997;96(9 suppl):II-286-II-290.
2. Kirklin JK. Prospects for understanding and eliminating the deleterious effects of cardiopulmonary bypass. Ann Thorac Surg. 1991;51:529-531.
3. Kirklin JK, Westaby S, Blackstone EH, Kirklin JW, Chenoweth DE, Pacifico AD. Complement and the damaging effects of cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1983;86:845-857.
4. Argenziano M, Chen JM, Choudhri AF, et al. Management of vasodilatory shock after cardiac surgery: identification of predisposing factors and use of a novel pressor agent. J Thorac Cardiovasc Surg. 1998;116:973-980.
5. Rozenfeld V, Cheng JW. The role of vasopressin in the treatment of vasodilation in shock states. Ann Pharmacother. 2000;34:250-254.
6. Morales DL, Gregg D, Helman DN, et al. Arginine vasopressin in the treatment of 50 patients with postcardiotomy vasodilatory shock. Ann Thorac Surg. 2000;69:102-106.
7. Parrillo JE, Parker MM, Natanson C, et al. Septic shock in humans: advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med. 1990;113:227-242.
8. Chernow B, Roth BL. Pharmacologic manipulation of the peripheral vasculature in shock: clinical and experimental approaches. Circ Shock. 1986;18:141-155.
9. Doris PA. Vasopressin and central integrative processes. Neuroendocrinology. 1984;38:75-85.
10. Pittman QJ, Wilkinson MF. Central arginine vasopressin and endogenous antipyresis. Can J Physiol Pharmacol. 1992;70:786-790.
11. Eichinger MR, Walker BR. Enhanced pulmonary arterial dilation to arginine vasopressin in chronically hypoxic rats. Am J Physiol. 1994;267:H2413-H2419.
12. Bichet DG, Razi M, Lonergan M, et al. Hemodynamic and coagulation responses to 1-desamino[8-d-arginine] vasopressin in patients with congenital nephrogenic diabetes insipidus. N Engl J Med. 1988;318:881-887.
13. Mannucci PM, Canciani MT, Rota L, Donovan BS. Response of factor VIII/von Willebrand factor to DDAVP in healthy subjects and patients with hemophilia A and von Willebrand's disease. Br J Haematol. 1981;47:283-293.
14. Snyder HM, Noland TD, Breyer MD. cAMP-dependent protein kinase mediates hydrosmotic effect of vasopressin in collecting duct. Am J Physiol. 1992;263:C147-C153.
15. Inaba K, Umeda Y, Yamane Y, Urakami M, Inada M. Characterization of human platelet vasopressin receptor and the relation between vasopressin-induced platelet aggregation and vasopressin binding to platelets. Clin Endocrinol (Oxf). 1988;29:377-386.
16. Keppens S, de Wulf H. The activation of liver glycogen phosphorylase by vasopressin. FEBS Lett. 1975;51:29-32.
17. Thibonnier M, Bayer AL, Leng Z. Cytoplasmic and nuclear signaling pathways of V1-vascular vasopressin receptors. Regul Pept. 1993;45:79-84.
18. Laszlo FA, Laszlo F Jr, De Wied D. Pharmacology and clinical perspectives of vasopressin antagonists. Pharmacol Rev. 1991;43:73-108.
19. Knepper MA, Nielsen S. Kinetic model of water and urea permeability regulation by vasopressin in collecting duct. Am J Physiol. 1993;265:F214-224.
20. Landry DW, Levin HR, Gallant EM, et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation. 1997;95:1122-1125.
21. Argenziano M, Chen JM, Cullinane S, et al. Arginine vasopressin in the management of vasodilatory hypotension after cardiac transplantation. J Heart Lung Transplant. 1999;18:814-817.
22. Rosenzweig EB, Stare TJ, Chen JM, et al. Intravenous arginine-vasopressin in children with vasodilatory shock after cardiac surgery. Circulation. 1999;100:II182-II186.
23. Cowley AW, Cushman WC, Quillen EW, Skelton MM, Langford HG. Vasopressin elevation in essential hypertension and increased responsiveness to sodium intake. Hypertension. 1981;3:I93-I100.
24. Morton JJ, Padfield PL, Forsling ML. A radioimmunoassay for plasma arginine-vasopressin in man and dog: application to physiological and pathological states. J Endocrinol. 1975;65:411-424.
25. Wu W, Zbuzek VK, Bellevue C. Vasopressin release during cardiac operation. J Thorac Cardiovasc Surg. 1980;79:83-90.
26. Levine FH, Philbin DM, Kono K, et al. Plasma vasopressin levels and urinary sodium excretion during cardiopulmonary bypass with and without pulsatile flow. Ann Thorac Surg. 1981;32:63-67.
27. Holmes CL, Patel BM, Russell JA, Walley KR. Physiology of vasopressin relevant to management of septic shock. Chest. 2001;120:989-1002.
28. Stump DL, Hardin TC. The use of vasopressin in the treatment of upper gastrointestinal haemorrhage. Drugs. 1990;39:38-53.
29. Arky R, ed. Physicians Desk Reference. 53rd ed. Montvale, NJ: Medical Economics Co; 1999:2776-2778.
30. Key DW, Bloom DA, Sanvordenker J. Low-dose DDAVP in nocturnal enuresis. Clin Pediatr (Phila). 1992;31:299-301.
31. Trissel LA, ed. Handbook of Injectable Drugs. 6th ed. Bethesda, Md: American Society of Hospital Pharmacists; 1990.
32. Rice TL. Treatment of esophageal varices. Clin Pharm. 1989;8:122-131.